NEW YORK, April 28 - In the latest phase of a restructuring plan that began in July 2002, Aclara today said it has let go an additional 30 employees, hired a new chief business officer, and appointed a new member to its board of directors.
Aclara said it carried out these steps with the goal of further increasing its focus on commercializing its eTag assay system - a strategy the company began implementing in July, when it first announced its restructuring plans and the elimination of 50 staffers.
Today, Aclara said it would eliminate an additional 30 positions in executive management, administration, marketing, and basic research, bringing its total headcount to 65.
"We believe these actions, while certainly difficult, allow us to focus on our most important priority, the commercialization and rapid adoption of eTag assays," said Thomas Klopack, Aclara's CEO, in a statement.
Michael Dunn, formerly executive VP of business development at Aurora Biosciences, will join the company to fill the new position of CBO, where he will be responsible for business development, sales, and marketing.
In addition, Affinium Pharmaceuticals CEO John Mendlein has been appointed to Aclara's board of directors.